According to Neurocrine Biosciences 's latest financial reports the company's total debt is $0.42 B. A companyโs total debt is the sum of all current and non-current debts.
Year | Total debt | Change |
---|---|---|
2023-12-31 | $0.42 B | 62.95% |
2022-12-31 | $0.26 B | -40.3% |
2021-12-31 | $0.44 B | 6.82% |
2020-12-31 | $0.41 B | -16.79% |
2019-12-31 | $0.49 B | 27.54% |
2018-12-31 | $0.38 B | 5.11% |
2017-12-31 | $0.36 B | |
2009-12-31 | $11.53 M | -25.12% |
2008-12-31 | $15.39 M | 936.14% |
2007-12-31 | $1.48 M | -97.23% |
2006-12-31 | $53.64 M | -9.7% |
2005-12-31 | $59.4 M | -10.17% |
2004-12-31 | $66.12 M | 81.5% |
2003-12-31 | $36.43 M | 359.14% |
2002-12-31 | $7.93 M | 39.53% |
2001-12-31 | $5.68 M |
Company | Total debt | differencediff. | Country |
---|---|---|---|
Pfizer PFE | $70.84 B | 16,437.11% | ๐บ๐ธ USA |
AbbVie ABBV | $59.38 B | 13,762.04% | ๐บ๐ธ USA |
Eli Lilly LLY | $25.22 B | 5,788.26% | ๐บ๐ธ USA |
Repligen
RGEN | $0.71 B | 66.15% | ๐บ๐ธ USA |
Athersys ATHX | $18.57 M | -95.66% | ๐บ๐ธ USA |
ANI Pharmaceuticals ANIP | $0.28 B | -33.32% | ๐บ๐ธ USA |
Palatin Technologies PTN | $0.82 M | -99.81% | ๐บ๐ธ USA |
Royalty Pharma RPRX | $6.13 B | 1,332.14% | ๐ฌ๐ง UK |